{
    "nctId": "NCT03709134",
    "briefTitle": "Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy",
    "officialTitle": "Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Breast Neoplasms, Cancer, Breast",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Pathologic complete response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects must give appropriate written informed consent prior to participation in the study.\n2. Subjects must be women or men age 18+.\n3. Subjects must be receiving neoadjuvant chemotherapy for breast cancer. All chemotherapy types and regimens are acceptable (systemic therapy will determined by the overseeing medical oncologist).\n4. Biopsy-confirmed diagnosis of invasive breast cancer (i.e. ER+/-, PR+/-, HER2+/-).\n5. Stage I-III disease according to the AJCC v7 criteria.\n\nExclusion Criteria:\n\n1. Subjects with a past medical history of abnormalities, significant injury, or medical or surgical procedures (e.g. silicone/saline implants) involving either breast, exclusive of the lesion at issue.\n2. Subjects, who, in the opinion of the investigator or clinical research coordinator, may not otherwise be appropriate for inclusion into the study, such as significant anxiety.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}